ConductScience.org, home

Paper26548664

Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro Behavior and tumor amelioration potential.

Padhi S and 7 others. Drug Deliv, 2016. Cited by 22 papers, by iCite.

Cite this record

ConductScience Library. Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro Behavior and tumor amelioration potential. Papers, record 26548664. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26548664

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro Behavior and tumor amelioration potential.
PubMed
Journal
Drug Deliv
PubMed
Year
2016
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
22
iCite
Relative citation ratio, by iCite
1.09
iCite
Revised in PubMed
2017-02-24
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Padhi SSantwana
2Mirza MAMohd Aamir
3Verma DDevina
4Khuroo TTahir
5Panda AKAmulya K
6Talegaonkar SSushama
7Khar RKRoop Krishen
8Iqbal ZZeenat

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug CarriersMajor topic
NanoparticlesMajor topic
NeoplasmsMajor topic
TopotecanMajor topic
Animals
Cell Line, Tumor
Chemistry, Pharmaceutical
Drug Delivery Systems
Emulsions
Mice
Particle Size

Source PubMed

Download CSV of topics

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.

PMIDTitleJournalYearIn PapersSource
37760469Resveratrol-Laden Nano-Systems in the Cancer Environment: Views and Reviews.Cancers (Basel)2023https://conductscience.org/library/papers/37760469PubMed
37663396Omega-3 fatty acid-based self-microemulsifying drug delivery system (SMEDDS) of pioglitazone: Optimization, in vitro and in vivo studies.Saudi J Biol Sci2023https://conductscience.org/library/papers/37663396PubMed
37376069Robust Inclusion Complex of Topotecan Comprised within a Rhodamine-Labeled β-Cyclodextrin: Competing Proton and Energy Transfer Processes.Pharmaceutics2023https://conductscience.org/library/papers/37376069PubMed
36937194The Antitumor Effect of Topotecan Loaded Thiolated Chitosan-Dextran Nanoparticles for Intravitreal Chemotherapy: A Xenograft Retinoblastoma Model.J Ophthalmic Vis Res2023https://conductscience.org/library/papers/36937194PubMed
36844532In Silico Guided Nanoformulation Strategy for Circumvention of Candida albicans Biofilm for Effective Therapy of Candidal Vulvovaginitis.ACS Omega2023https://conductscience.org/library/papers/36844532PubMed
36831009Nano-Enabled Strategies for the Treatment of Lung Cancer: Potential Bottlenecks and Future Perspectives.Biomedicines2023https://conductscience.org/library/papers/36831009PubMed
36612067Nanoplatform for the Delivery of Topotecan in the Cancer Milieu: An Appraisal of its Therapeutic Efficacy.Cancers (Basel)2022https://conductscience.org/library/papers/36612067PubMed
35983007A Critical Scrutiny on Liposomal Nanoparticles Drug Carriers as Modelled by Topotecan Encapsulation and Release in Treating Cancer.Evid Based Complement Alternat Med2022https://conductscience.org/library/papers/35983007PubMed
35812154Abemaciclib-loaded ethylcellulose based nanosponges for sustained cytotoxicity against MCF-7 and MDA-MB-231 human breast cancer cells lines.Saudi Pharm J2022https://conductscience.org/library/papers/35812154PubMed
35811933Impact of Composition and Morphology of Ketoconazole-Loaded Solid Lipid Nanoparticles on Intestinal Permeation and Gastroplus-Based Prediction Studies.ACS Omega2022https://conductscience.org/library/papers/35811933PubMed
35721949Ketoconazole-Loaded Cationic Nanoemulsion: In Vitro-Ex Vivo-In Vivo Evaluations to Control Cutaneous Fungal Infections.ACS Omega2022https://conductscience.org/library/papers/35721949PubMed
35012125Development and Optimization of Acriflavine-Loaded Polycaprolactone Nanoparticles Using Box-Behnken Design for Burn Wound Healing Applications.Polymers (Basel)2021https://conductscience.org/library/papers/35012125PubMed
32550804Design of expert guided investigation of native L-asparaginase encapsulated long-acting cross-linker-free poly (lactic-co-glycolic) acid nanoformulation in an Ehrlich ascites tumor model.Saudi Pharm J2020https://conductscience.org/library/papers/32550804PubMed
31546717Rapid Microfluidic Preparation of Niosomes for Targeted Drug Delivery.Int J Mol Sci2019https://conductscience.org/library/papers/31546717PubMed
29029577A novel core-shell lipid nanoparticle for improving oral administration of water soluble chemotherapeutic agents: inhibited intestinal hydrolysis and enhanced lymphatic absorption.Drug Deliv2017https://conductscience.org/library/papers/29029577PubMed
28671589Theranostic Liposome-Nanoparticle Hybrids for Drug Delivery and Bioimaging.Int J Mol Sci2017https://conductscience.org/library/papers/28671589PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26548664

GET https://conductscience.org/api/papers/v1/26548664/authors